STAAR Surgical to Host Investor Breakfast and Webcast during the American Academy of Ophthalmology's Annual Meeting
Dr.
Investors participating in AAO and interested in attending the breakfast meeting, should contact
About
STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." Over 375,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 full time employees and markets lenses in over 60 countries. Headquartered in
Collamer® is the registered trademark for STAAR's proprietary biocompatible collagen copolymer lens material.
Safe Harbor
All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: the plans, strategies, and objectives of management for future operations or prospects for achieving such plans, including but not limited to, statements regarding new products, CE Mark approval and launch of the Visian ICL Preloaded System, and plans for the Visian V6, as well as expectations for success of these products in the U.S. or international markets or government approval of them, and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. Important additional factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's Annual Report on Form 10-K for the year ended
CONTACT: |
Investors |
Media |
EVC Group |
EVC Group |
|
Doug Sherk, 415-652-9100 |
Janine McCargo |
|
Leigh Salvo, 415-568-9348 |
646-688-0425 |
SOURCE